Wall Street Zen Downgrades Protagonist Therapeutics (NASDAQ:PTGX) to Buy

Protagonist Therapeutics (NASDAQ:PTGX) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

Several other equities analysts have also issued reports on PTGX. Weiss Ratings reissued a “sell (d+)” rating on shares of Protagonist Therapeutics in a report on Friday, May 15th. Truist Financial lifted their target price on Protagonist Therapeutics from $121.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. TD Cowen reissued a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, July 1st. Citigroup increased their price target on Protagonist Therapeutics from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Zacks Research raised Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $126.71.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX opened at $145.87 on Friday. The firm’s 50 day simple moving average is $124.30 and its 200 day simple moving average is $105.38. Protagonist Therapeutics has a fifty-two week low of $50.49 and a fifty-two week high of $148.00. The company has a market capitalization of $9.38 billion, a price-to-earnings ratio of 141.62 and a beta of 1.78.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.02. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The firm had revenue of $213.47 million during the quarter, compared to analysts’ expectations of $212.03 million. The business’s quarterly revenue was up 3746.8% on a year-over-year basis. Equities research analysts expect that Protagonist Therapeutics will post 3.51 earnings per share for the current year.

Insider Transactions at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the sale, the chief executive officer directly owned 523,478 shares in the company, valued at $52,410,617.36. The trade was a 12.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director William D. Waddill sold 9,000 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total value of $1,061,460.00. Following the transaction, the director directly owned 7,825 shares of the company’s stock, valued at $922,880.50. This represents a 53.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 102,000 shares of company stock valued at $10,436,340. Corporate insiders own 5.19% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Protagonist Therapeutics during the 2nd quarter worth approximately $1,263,535,000. Vanguard Group Inc. raised its holdings in shares of Protagonist Therapeutics by 27.2% in the fourth quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock valued at $472,832,000 after purchasing an additional 1,156,461 shares during the last quarter. State Street Corp lifted its position in shares of Protagonist Therapeutics by 18.5% in the second quarter. State Street Corp now owns 3,207,543 shares of the company’s stock worth $177,281,000 after purchasing an additional 500,924 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Protagonist Therapeutics by 66.2% in the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock worth $276,992,000 after purchasing an additional 1,262,977 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Protagonist Therapeutics by 9.1% in the first quarter. Janus Henderson Group PLC now owns 2,891,527 shares of the company’s stock worth $304,866,000 after purchasing an additional 241,546 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics News Summary

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Protagonist reported quarterly earnings of $2.29 per share, exceeding the $2.27 analyst consensus, while revenue of $213.48 million also topped expectations. The results represent substantial year-over-year revenue growth and helped push PTGX to a new one-year high. Protagonist Therapeutics Reaches New 1-Year High on Earnings Beat
• Positive Sentiment: Citigroup raised its price target for PTGX to $175, signaling additional potential upside from recent trading levels and continued analyst confidence in the company’s outlook. Citigroup Raises Protagonist Therapeutics Price Target to $175
• Neutral Sentiment: Wall Street Zen changed its rating on Protagonist Therapeutics to Buy. Although the rating is bullish, the report describes the move as a downgrade, suggesting the change may reflect a less aggressive stance than the firm’s prior view. Protagonist Therapeutics Downgraded by Wall Street Zen to Buy
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to $4.00 from $4.72 and cut its fourth-quarter 2026 forecast to a loss of $0.90 per share from a loss of $0.76. The firm also projects losses in FY2027 and FY2028, adding pressure to near-term valuation despite its FY2026 estimate remaining above the broader consensus of $3.69. HC Wainwright Analysts Decrease Earnings Estimates for PTGX

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.